Related references
Note: Only part of the references are listed.Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease
Jacob E. Ollech et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab
Anne Hu et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis
Clara Yzet et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
The impact of ustekinumab on extraintestinal manifestations of Crohn's disease: A post hoc analysis of the UNITI studies
Neeraj Narula et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2021)
Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naive and Anti-TNF Exposed IBD Patients
Bram Verstockt et al.
JOURNAL OF CROHNS & COLITIS (2020)
Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial
Xavier Roblin et al.
GUT (2020)
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study
Aurelien Amiot et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor
Hadrien Alric et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy
Uri Kopylov et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment
Vince B. C. Biemans et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series
Frank M. Phillips et al.
JOURNAL OF CROHNS & COLITIS (2020)
Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' reply
Hadrien Alric et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry
Marisa Iborra et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
Matthew Bohm et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab
Liza Kassouri et al.
DIGESTIVE AND LIVER DISEASE (2020)
Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study
Nathaniel Aviv Cohen et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2020)
Good efficacy and safety of vedolizumab in Crohn's disease and ulcerative colitis in a real-world scenario
Fabiana Zingone et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)
Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases
Brian G. Feagan et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates
Bram Verstockt et al.
JOURNAL OF CROHNS & COLITIS (2019)
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study
Claire Liefferinckx et al.
JOURNAL OF CROHNS & COLITIS (2019)
Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidence
Tal Engel et al.
DIGESTIVE AND LIVER DISEASE (2019)
Vedolizumab in IBD-Lessons From Real-world Experience; A Systematic Review and Pooled Analysis
Tal Engel et al.
JOURNAL OF CROHNS & COLITIS (2018)
Efficacy of vedolizumab for induction of clinical response and remission in patients with moderate to severe inflammatory bowel disease who failed at least two TNF antagonists
Martine De Vos et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2018)
Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience
P. Wils et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease
A. Barre et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naive Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study
Uri Kopylov et al.
INFLAMMATORY BOWEL DISEASES (2018)
Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety
Britt Christensen et al.
INFLAMMATORY BOWEL DISEASES (2018)
Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease
Stefan Schreiber et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease
Marla C. Dubinsky et al.
INFLAMMATORY BOWEL DISEASES (2018)
Clinical efficacy and safety of golimumab in biologically experienced and naive patients with active ulcerative colitis: A real-life experience from two Italian IBD centers
Beatrice Orlandini et al.
JOURNAL OF DIGESTIVE DISEASES (2018)
Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response
E. Dreesen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naive and non-naive patients
Marisa Iborra et al.
JOURNAL OF GASTROENTEROLOGY (2017)
Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease-the Israeli Real-World Experience
Uri Kopylov et al.
INFLAMMATORY BOWEL DISEASES (2017)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naive to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy
Bruce E. Sands et al.
INFLAMMATORY BOWEL DISEASES (2017)
Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease
Robert Battat et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab
Jessica R. Allegretti et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort
C. Ma et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study
D. C. Baumgart et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study
A. Stallmach et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium
Parambir S. Dulai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease
Uri Kopylov et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2016)
Ustekinumab in Crohn's disease: evidence to date and place in therapy
Tal Engel et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2016)
Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?
Javier P. Gisbert et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2015)
Optimizing anti-TNF treatments in inflammatory bowel disease
Shomron Ben-Horin et al.
AUTOIMMUNITY REVIEWS (2014)
Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease-The McGill experience
U. Kopylov et al.
JOURNAL OF CROHNS & COLITIS (2014)
Tailoring anti-TNF therapy in IBD: drug levels and disease activity
Shomron Ben-Horin et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2014)
Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease
P. S. A. de Silva et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Share Paper
